Erdafitinib

• A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting
  2024-519493-39-00 Phase III 7 countries Janssen Cilag International
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt… Recruiting
  2023-507684-19-00 Phase III 10 countries Janssen Cilag International
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monothera… Ended
  2024-512573-27-01 Phase II 3 countries Grupo Espanol De Oncologia Genitourinaria-Socug
• A study to evaluate the safety, the distribution and elimination of the compound in the body, and the effectiveness of Erdafitinib by itself… Ended
  2023-510295-31-00 Phase I/II 1 country Janssen Cilag International
• An Efficacy and Safety Study of JNJ-42756493 in Participants with Urothelial Cancer Ended
  2023-510273-34-00 Phase II 2 countries Janssen Cilag International
• A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette… Ended
  2023-510306-40-00 Phase II 3 countries Janssen Cilag International
• A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations Ended
  2023-510301-18-00 Phase II 2 countries Janssen Cilag International
• A Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Urothelial Cancer Ended
  2023-510296-56-00 Phase III 3 countries Janssen Cilag International

Showing 1–9 of 9 trials